Todd C. Zion
Affiliations: | Nanostructured Materials Research Laboratory - MIT |
Google:
"Todd Zion"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Alleva DG, Delpero AR, Sathiyaseelan T, et al. (2024) An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes. Frontiers in Immunology. 15: 1367514 |
| Alleva DG, Feitsma EA, Janssen YF, et al. (2024) Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine. Npj Vaccines. 9: 40 |
| Feitsma EA, Janssen YF, Boersma HH, et al. (2023) A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine |
| Hulsebosch SE, Pires J, Bannasch MJ, et al. (2022) Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs. Journal of Veterinary Internal Medicine |
| Janssen YF, Feitsma EA, Boersma HH, et al. (2022) Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 40: 1253-1260 |
| Alleva DG, Delpero AR, Scully MM, et al. (2021) Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine |
| Gilor C, Hulsebosch SE, Pires J, et al. (2021) An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats. Journal of Veterinary Internal Medicine |
| Fettig LM, Zhang X, LaPara K, et al. (2020) Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth Cancer Research. 80 |